Ballegaard C, et al. – This study outlined the impact of comorbidities on disease activity, treatment response and persistence with the first–tried tumor necrosis factor inhibitor (TNFi) in patients with psoriatic arthritis (PsA). Investigations revealed that the presence of comorbidities was associated with higher baseline disease activity, shorter TNFi persistence and reduced clinical response rates in patients with PsA.